UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Refining the use of cabazitaxel in metastatic castrate-resistant prostate cancer

European journal of cancer (1990), 2018-07, Vol.97, p.30-32

Culine, Stéphane

2018

Volltextzugriff (PDF)

Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step

European urology, 2018-07, Vol.74 (1), p.24-25

Culine, Stéphane

2018

Volltextzugriff (PDF)

Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial Secondary Endpoints: Chemotherapy Toxicity and Pathological Responses

European urology, 2021-02, Vol.79 (2), p.214-221

2021

Volltextzugriff (PDF)

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial

Journal of clinical oncology, 2022-06, Vol.40 (18), p.2013-2022

2022

Volltextzugriff (PDF)

Perioperative chemotherapy in bladder cancer: the more cisplatin, the best survival?

World journal of urology, 2024-03, Vol.42 (1), p.140-140, Article 140

2024

Volltextzugriff (PDF)

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

The New England journal of medicine, 2017-03, Vol.376 (11), p.1015-1026

2017

Volltextzugriff (PDF)

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

Journal of clinical oncology, 2009-09, Vol.27 (27), p.4454-4461

2009

Volltextzugriff (PDF)

Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens

Journal of clinical oncology, 2010-04, Vol.28 (11), p.1850-1855

2010

Volltextzugriff (PDF)

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study

Journal of clinical oncology, 2019-08, Vol.37 (23), p.2008-2016

2019

Volltextzugriff (PDF)

Cetuximab in advanced bladder cancer

Journal of clinical oncology, 2013-04, Vol.31 (12), p.1614-1615

Culine, Stéphane

2013

Volltextzugriff (PDF)

miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice

PloS one, 2009-10, Vol.4 (10), p.e7542-e7542

2009

Volltextzugriff (PDF)

Prognostic Factors in Unknown Primary Cancer

Seminars in oncology, 2009-02, Vol.36 (1), p.60-64

Culine, Stéphane

2009

Volltextzugriff (PDF)

Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis

Drugs & aging, 2020-10, Vol.37 (10), p.747-754

2020

Volltextzugriff (PDF)

High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor

European urology, 2008-02, Vol.53 (2), p.376-381

2008

Volltextzugriff (PDF)

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

Journal of clinical oncology, 2021-05, Vol.39 (14), p.1553-1562

2021

Volltextzugriff (PDF)

External Validity of Two Scores for Predicting the Risk of Chemotherapy Toxicity Among Older Patients With Solid Tumors: Results From the ELCAPA Prospective Cohort

The oncologist (Dayton, Ohio), 2023-06, Vol.28 (6), p.e341-e349

2023

Volltextzugriff (PDF)

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

The lancet oncology, 2015-07, Vol.16 (7), p.787-794

2015

Volltextzugriff (PDF)

Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS)

BMC cancer, 2021-02, Vol.21 (1), p.117-10, Article 117

2021

Volltextzugriff (PDF)

Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer

European journal of cancer (1990), 2017-09, Vol.83, p.211-219

2017

Volltextzugriff (PDF)

Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder

Radiotherapy and oncology, 2021-08, Vol.161, p.95-114

2021

Volltextzugriff (PDF)

Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial

European urology, 2021-09, Vol.80 (3), p.325-329

2021

Volltextzugriff (PDF)

Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice

Molecular cancer therapeutics, 2010-06, Vol.9 (6), p.1740-1754

2010

Volltextzugriff (PDF)

Short-course treatment after complete response to pembrolizumab in metastatic urothelial bladder cancer: a case series

Immunotherapy, 2023-07, Vol.15 (10), p.729-735

2023

Volltextzugriff (PDF)

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study

The lancet oncology, 2024-02, Vol.25 (2), p.255-264

2024

Volltextzugriff (PDF)

1 – 25 von 426

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(394)
Mit Volltextzugriff
(342)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(240)
Humans
(239)
Life Sciences & Biomedicine
(239)
Oncology
(172)
Male
(164)
Aged
(106)
Middle Aged
(101)
Female
(88)
Biological And Medical Sciences
(87)
Medical Sciences
(87)
Chemotherapy
(83)
Adult
(76)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(72)
Life Sciences
(62)
Urology & Nephrology
(62)
Treatment Outcome
(56)
Cancer
(55)
Prognosis
(51)
Tumors
(51)
Aged, 80 And Over
(44)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(3)

Menü

Weitere Dienste

Einstellungen

Refining the use of cabazitaxel in metastatic castrate-resistant prostate cancer

Customizing Daily Management of Castrate-resistant Prostate Cancer: Waiting for the Next Step

Androgen Deprivation Therapy (ADT) Plus Docetaxel Versus ADT Alone in Metastatic Non castrate Prostate Cancer: Impact of Metastatic Burden and Long-term Survival Analysis of the Randomized Phase 3 GETUG-AFU15 Trial

Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients With Nonmetastatic Muscle-Invasive Bladder Cancer: Results of the GETUG-AFU V05 VESPER Trial

Perioperative chemotherapy in bladder cancer: the more cisplatin, the best survival?

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract

Prognostic Factors in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract Experiencing Treatment Failure With Platinum-Containing Regimens

Safety and Efficacy of Nivolumab in Brain Metastases From Renal Cell Carcinoma: Results of the GETUG-AFU 26 NIVOREN Multicenter Phase II Study

Cetuximab in advanced bladder cancer

miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice

Prognostic Factors in Unknown Primary Cancer

Immune Checkpoint Inhibitors for Patients Aged ≥ 75 Years with Advanced Cancer in First- and Second-Line Settings: A Meta-Analysis

High Frequency of Intracerebral Hemorrhage in Metastatic Renal Carcinoma Patients with Brain Metastases Treated with Tyrosine Kinase Inhibitors Targeting the Vascular Endothelial Growth Factor Receptor

Survival and New Prognosticators in Metastatic Seminoma: Results From the IGCCCG-Update Consortium

External Validity of Two Scores for Predicting the Risk of Chemotherapy Toxicity Among Older Patients With Solid Tumors: Results From the ELCAPA Prospective Cohort

Androgen deprivation therapy plus docetaxel and estramustine versus androgen deprivation therapy alone for high-risk localised prostate cancer (GETUG 12): a phase 3 randomised controlled trial

Efficacy of extracranial stereotactic body radiation therapy (SBRT) added to standard treatment in patients with solid tumors (breast, prostate and non-small cell lung cancer) with up to 3 bone-only metastases: study protocol for a randomised phase III trial (STEREO-OS)

Prognostic value of the G8 and modified-G8 screening tools for multidimensional health problems in older patients with cancer

Recommendations for planning and delivery of radical radiotherapy for localized urothelial carcinoma of the bladder

Primary Renal Tumour Response in Patients Treated with Nivolumab for Metastatic Renal Cell Carcinoma: Results from the GETUG-AFU 26 NIVOREN Trial

Abrogation of de novo lipogenesis by stearoyl-CoA desaturase 1 inhibition interferes with oncogenic signaling and blocks prostate cancer progression in mice

Short-course treatment after complete response to pembrolizumab in metastatic urothelial bladder cancer: a case series

Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study

Suchergebnisse filtern